04/02/2026
We’re excited to share an important milestone at Hoopes Vision.
Dr. Majid Moshirfar participated in early FDA clinical trials studying a new Epithelium-On Corneal Cross-Linking (Epi-On CXL) approach for patients with keratoconus, which has recently gained FDA approval. “This new Epi-On procedure is more comfortable for our patients, and the recovery is much faster,” says Dr. Moshirfar.
CXL is designed to help strengthen the cornea and slow the progression of keratoconus, a condition that can worsen vision over time. Glaukos selected Hoopes Vision as one of the research sites to study this new technology. Several of our patients were among the 590 subjects who completed this study.
This opportunity helped us better understand how this technology may support our patients with keratoconus.
As leaders in modern vision correction, we’re proud to continue advancing care through research, technology, and patient-centered treatment options. Because of our research center, our patients often have access to newer technology not available to the general public.
If you or someone you know has been diagnosed with keratoconus, our team is here to help you understand your options. Schedule a consultation to learn more.
From left to right- Drs. Benjamin Bucker, Michael Bradley, Majid Moshirfar.
Learn about corneal cross-linking surgery near you at Hoopes Vision. Strengthen your cornea and improve your vision with expert care. Visit us!